Clinical trial
Effect of Tocopherol and Ascorbic Acid on Neuroinflammation Markers Associated With Neuropeptide Expression in the AgRP/NPY and POMC Pathways in Mexican Population With Obesity
Opening soon · Not applicable · 1 countries · Registry ID NCT07782411
What this study is about
This clinical trial will determine whether taking ascorbic acid (vitamin C), α-tocopherol (vitamin E), or both together can lower markers of brain inflammation and change the expression of neuropeptides in Mexican adults with obesity. Main Questions The study aims to answer: 1. Does vitamin C, vitamin E, or both reduce neuroinflammation? 2. Do these supplements change the expression of neuropeptides linked to obesity? Comparison Groups Researchers will compare the effects of vitamin C alone, vitamin E alone, and the combination of both to see if they improve brain health in people with obesity. What Participants Will Do Participants will: 1. Take vitamin C, vitamin E, or both daily, depending on their assigned group 2. Attend clinic visits once every 2 weeks for and tests for checkups and tests for record and report supplement intake so that researchers can monitor and evaluate treatment adherence 3. Provide samples and health information to measure inflammation and neuropeptides , at the beginning of the intervention and at 12 weeks, when the intervention ends.
Basic eligibility
Full registry criteria
Treatments and study arms
Ascorbic acid (Vitamin C)
Participants will receive 1000 mg of ascorbic acid orally once daily for 12 weeks. The intervention is administered in tablet form and aims to evaluate the therapeutic effect of ascorbic acid supplementation in the Biomarkers of neuroinflammation and neuropeptide expression
tocopherol alpha
Participants will receive 800 mg of tocopherol orally once daily for 12 weeks. The intervention is administered in tablet form and aims to evaluate the therapeutic effect of tocopherol supplementation in the Biomarkers of neuroinflammation and neuropeptide expression
Ascorbic acid + tocopherol alpha
Participants will receive 1000mg of ascorbic acid + 800 mg of tocopherol orally once daily for 12 weeks. The intervention is administered in tablet form and aims to evaluate the therapeutic effect ofsupplementation in the Biomarkers of neuroinflammation and neuropeptide expression
Primary outcomes
Variation in the expression levels of pro-inflammatory cytokines (IL-1β, TNF-α, IL-8) and glial activation proteins (GFAP, S100B) will be assessed as indicators of neuroinflammatory processes.
Study locations
1 locations were listed when this page was built. The first 40 are shown.